CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 277 filers reported holding CRISPR THERAPEUTICS AG in Q2 2020. The put-call ratio across all filers is 1.18 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $2,625,177 | +78.0% | 64,580 | +186.2% | 0.01% | +40.0% |
| Q3 2022 | $1,475,000 | +235.2% | 22,562 | +221.6% | 0.01% | +400.0% |
| Q1 2022 | $440,000 | -0.7% | 7,016 | +20.0% | 0.00% | -50.0% |
| Q4 2021 | $443,000 | -63.0% | 5,847 | -45.3% | 0.00% | -60.0% |
| Q3 2021 | $1,196,000 | +128.7% | 10,688 | +212.7% | 0.01% | +66.7% |
| Q4 2020 | $523,000 | -93.7% | 3,418 | -96.6% | 0.00% | -95.1% |
| Q3 2020 | $8,347,000 | +1805.7% | 99,802 | +1573.7% | 0.06% | +1425.0% |
| Q2 2020 | $438,000 | -91.5% | 5,963 | -94.6% | 0.00% | -87.9% |
| Q2 2019 | $5,165,000 | -44.7% | 109,657 | -39.1% | 0.03% | -21.4% |
| Q3 2018 | $9,340,000 | -61.7% | 180,000 | -56.7% | 0.04% | -62.2% |
| Q2 2018 | $24,415,000 | – | 415,500 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 508,558 | $82,330,000 | 27.28% |
| Valiant Capital Management, L.P. | 307,700 | $49,814,000 | 3.74% |
| NEA Management Company, LLC | 1,590,002 | $257,405,000 | 3.35% |
| NIA IMPACT ADVISORS, LLC | 39,891 | $6,458,000 | 3.15% |
| Ikarian Capital, LLC | 200,000 | $32,379,000 | 2.62% |
| Soleus Capital Management, L.P. | 103,114 | $16,693,000 | 2.57% |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 157,334 | $25,471,000 | 2.47% |
| Capital Impact Advisors, LLC | 45,440 | $7,356,000 | 2.37% |
| ARK Investment Management | 7,776,119 | $1,258,876,000 | 2.34% |
| Sassicaia Capital Advisers LLC | 13,513 | $2,188,000 | 2.28% |